



## **Anaergia Inc.**

Condensed Consolidated Interim Financial Statements  
(Unaudited)  
(in thousands of Canadian Dollars)

**ANAERGIA INC.**

**CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION**

As of March 31, 2025 and December 31, 2024

All amounts in thousands of Canadian Dollars

	Notes	March 31, 2025 (unaudited) \$	December 31, 2024 \$
<b>ASSETS</b>			
<b>Current assets</b>			
Cash		20,775	30,220
Restricted cash		12,376	14,769
Trade and other receivables		27,010	26,934
Contract assets		14,044	10,757
Prepaid expenses		2,872	3,754
Inventories		9,808	8,425
Other current assets		11,162	9,359
<b>Total current assets</b>		<b>98,047</b>	<b>104,218</b>
<b>Non-current assets</b>			
Restricted cash		287	287
Property, plant and equipment, net	6	107,504	108,203
Intangible assets, net	6	2,516	2,560
Deferred tax assets		4,495	4,068
Other long-term assets		10,181	13,991
<b>Total non-current assets</b>		<b>124,983</b>	<b>129,109</b>
<b>Total assets</b>		<b>223,030</b>	<b>233,327</b>

*See notes to the condensed consolidated interim financial statements.*

**ANAERGIA INC.**

**CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION**

As of March 31, 2025 and December 31, 2024

All amounts in thousands of Canadian Dollars

	Notes	March 31, 2025 (unaudited) \$	December 31, 2024 \$
<b>Current liabilities</b>			
Accounts payable		29,323	28,598
Accrued liabilities and provisions		26,799	30,242
Taxes payables		7,612	7,472
Current portion of deferred government grants		286	4,791
Current portion of contract liabilities		22,550	17,939
Current portion of lease liabilities		2,296	2,273
Current portion of long-term debt	8	32,258	32,334
<b>Total current liabilities</b>		<b>121,124</b>	<b>123,649</b>
<b>Non-current liabilities</b>			
Long-term portion of deferred government grants		3,426	4,608
Long-term portion of contract liabilities		1,661	1,634
Long-term portion of lease liabilities		8,966	9,297
Long-term debt	8	27,713	27,806
Asset retirement obligations		2,589	2,562
Deferred tax liabilities		4,158	6,794
Derivative liability		1,141	733
Other long-term liabilities		2,995	3,039
<b>Total non-current liabilities</b>		<b>52,649</b>	<b>56,473</b>
<b>Total liabilities</b>		<b>173,773</b>	<b>180,122</b>
<b>SHAREHOLDERS' EQUITY</b>			
Non-controlling interests	9	111,073	110,850
Issued capital	9	439,360	439,315
Contributed surplus	9	7,556	7,350
Deficit		(522,907)	(522,781)
Accumulated other comprehensive income		14,175	18,471
<b>Total equity</b>		<b>49,257</b>	<b>53,205</b>
<b>Total liabilities and equity</b>		<b>223,030</b>	<b>233,327</b>

Commitments and contingencies Note 11

*See notes to the condensed consolidated interim financial statements.*

On behalf of the board:

/s/ Ohad Epschtein Director /s/ Peter Gross Director

**ANAERGIA INC.**

**CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS**

For the three months ended March 31, 2025 and 2024

All amounts in thousands of Canadian Dollars, except per share amounts, Unaudited

		<b>Three Months Ended March 31,</b>	
	<b>Notes</b>	<b>2025</b>	<b>2024</b>
		<b>\$</b>	<b>\$</b>
Revenue	12	24,876	24,969
Cost of sales		19,473	18,489
<b>Gross profit</b>		<b>5,403</b>	<b>6,480</b>
Selling, general, and administrative expenses		17,176	16,607
Research and development expenses		24	307
Government grant income		(6,127)	(224)
<b>Operating expenses</b>		<b>11,073</b>	<b>16,690</b>
<b>Loss from operations</b>		<b>(5,670)</b>	<b>(10,210)</b>
Losses related to equity-accounted investees	7	—	(478)
Other losses, net		(809)	(320)
Finance costs, net		(1,016)	(1,035)
Foreign exchange gain (losses)		(288)	545
		(2,113)	(1,288)
<b>Loss before income taxes</b>		<b>(7,783)</b>	<b>(11,498)</b>
Income tax recovery		1,886	17
<b>Net loss</b>		<b>(5,897)</b>	<b>(11,481)</b>
<b>Net loss attributable to:</b>			
Shareholders		(2,985)	(7,385)
Non-controlling interests		(2,912)	(4,096)
		<b>(5,897)</b>	<b>(11,481)</b>
<b>Basic and diluted loss per share</b>	13	<b>(0.02)</b>	<b>(0.09)</b>

*See notes to the condensed consolidated interim financial statements.*

**ANAERGIA INC.**

**CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS**

For the three months ended March 31, 2025 and 2024

All amounts in thousands of Canadian Dollars, Unaudited

	Notes	Three Months Ended March 31,	
		2025	2024
		\$	\$
<b>Net loss</b>		<b>(5,897)</b>	<b>(11,481)</b>
<b>Items that may be reclassified back to profit or loss in future periods</b>			
Exchange difference on translation of foreign operations		672	964
Fair value losses related to hedging transaction		(393)	(150)
<b>Total comprehensive loss</b>		<b>(5,618)</b>	<b>(10,667)</b>
<b>Total comprehensive loss attributable to:</b>			
Shareholders		(7,216)	(7,161)
Non-controlling interests		1,598	(3,506)
		<b>(5,618)</b>	<b>(10,667)</b>

*See notes to the condensed consolidated interim financial statements.*

**ANAERGIA INC.**

**CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY**

For the three months ended March 31, 2025

All amounts in thousands of Canadian Dollars, Unaudited

	Issued Share Capital	Contributed Surplus	Deficit	Accumulated Other Comprehensive Income (Loss) - Currency Translation Reserve	Total	Non- controlling Interests	Total Equity
	\$	\$	\$	\$	\$	\$	\$
<b>As at January 1, 2025</b>	439,315	7,350	(522,781)	18,471	(57,645)	110,850	53,205
Net loss	—	—	(2,985)	—	(2,985)	(2,912)	(5,897)
Other comprehensive loss - hedging	—	—	—	(1,175)	(1,175)	782	(393)
Other comprehensive loss - foreign currency translation	—	—	—	(3,056)	(3,056)	3,728	672
Total comprehensive loss	—	—	(2,985)	(4,231)	(7,216)	1,598	(5,618)
Preferred share issuance to non-controlling interests (Note 9)	—	—	—	—	—	1,419	1,419
RSU Vesting and Option Exercises (Note 10)	45	(44)	—	—	1	—	1
Profit sharing arrangement - Anaergia Bioenergy Facilities (Note 9)	—	—	894	(65)	829	(829)	—
Profit sharing arrangement - Rhode Island Bioenergy Facilities (Note 9)	—	—	1,965	—	1,965	(1,965)	—
Share based compensation (Note 10)	—	250	—	—	250	—	250
<b>As at March 31, 2025</b>	<b>439,360</b>	<b>7,556</b>	<b>(522,907)</b>	<b>14,175</b>	<b>(61,816)</b>	<b>111,073</b>	<b>49,257</b>

*See notes to the condensed consolidated interim financial statements.*

**ANAERGIA INC.**

**CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY**

For the three months ended March 31, 2024

All amounts in thousands of Canadian Dollars, Unaudited

	Issued Share Capital	Contributed Surplus	Deficit	Accumulated Other Comprehensive Income (Loss) - Currency Translation Reserve	Total	Non- controlling Interests	Total Equity
	\$	\$	\$	\$	\$	\$	\$
<b>As at January 1, 2024</b>	397,831	8,066	(479,222)	17,942	(55,383)	128,973	73,590
Net loss	—	—	(7,385)	—	(7,385)	(4,096)	(11,481)
Other comprehensive loss - hedging	—	—	—	(76)	(76)	(74)	(150)
Other comprehensive gain - foreign currency translation	—	—	—	300	300	664	964
Total comprehensive loss	—	—	(7,385)	224	(7,161)	(3,506)	(10,667)
Issuance of shares (Note 9)	12,502	—	—	—	12,502	—	12,502
Preferred distribution to non-controlling interest	—	—	—	—	—	(7,949)	(7,949)
Exercise of stock options (Note 10)	68	(68)	—	—	—	—	—
Profit sharing arrangement - Anaergia Bioenergy Facilities	—	—	5,572	(3,093)	2,479	(2,479)	—
Profit sharing arrangement - Rhode Island Bioenergy Facilities	—	—	9,294	(1,204)	8,090	(8,090)	—
Share based compensation (Note 10)	—	589	—	—	589	—	589
<b>As at March 31, 2024</b>	<b>410,401</b>	<b>8,587</b>	<b>(471,741)</b>	<b>13,869</b>	<b>(38,884)</b>	<b>106,949</b>	<b>68,065</b>

*See notes to the condensed consolidated interim financial statements.*

**ANAERGIA INC.**

**CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS**

For the three months ended March 31, 2025 and 2024

All amounts in thousands of Canadian Dollars, Unaudited

		<b>Three Months Ended March 31,</b>	
	<b>Notes</b>	<b>2025</b>	<b>2024</b>
		<b>\$</b>	<b>\$</b>
<b>OPERATING ACTIVITIES</b>			
Net loss		(5,897)	(11,481)
<b>Adjustments for the following non-cash items:</b>			
Depreciation and amortization		1,480	1,186
Income tax recovery		1,886	17
Finance costs		1,016	1,035
Share based compensation expense	10	250	589
Expected credit losses		1,561	806
Losses related to equity-accounted investees	7	—	478
Government grant income		(6,126)	(224)
Other losses		809	320
RIBF income tax credit transaction cost		—	2,416
Net change in operating assets and liabilities	14	(2,596)	(3,720)
Net cash (used in) received for income taxes		(121)	45
<b>Cash used in operating activities</b>		<b>(7,738)</b>	<b>(8,533)</b>
<b>INVESTING ACTIVITIES</b>			
Purchase of property, plant and equipment		(323)	(1,414)
Investment in intangible assets		(13)	—
Proceeds from the sale of income tax credits		—	21,679
<b>Cash provided by (used) in investing activities</b>		<b>(336)</b>	<b>20,265</b>
<b>FINANCING ACTIVITIES</b>			
Restricted cash utilization		2,393	1,851
Proceeds from exercise of stock options		1	—
Proceeds from grant funding		439	—
Proceeds from issuance of share capital		—	12,502
Proceeds from issuance of preferred capital in a subsidiary		1,419	—
Distributions to non-controlling interests		—	(7,949)
Lease payments		(428)	(587)
Payment of interest	8	(1,104)	(1,122)
Repayment of debt	8	(1,087)	(765)
<b>Cash provided by financing activities</b>		<b>1,633</b>	<b>3,930</b>
<b>Effect of exchange rate differences</b>		<b>(3,004)</b>	<b>(33)</b>
<b>Net change in cash during the period</b>		<b>(9,445)</b>	<b>15,629</b>
<b>Cash, beginning of period</b>		<b>30,220</b>	<b>22,113</b>
<b>Cash, end of period</b>		<b>20,775</b>	<b>37,742</b>

*See notes to the condensed consolidated interim financial statements.*



## ANAERGIA INC.

### NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three months ended March 31, 2025 and 2024

All amounts in thousands of Canadian Dollars,  
except share and per share amounts

#### 1. Corporate information

Anaergia Inc. (the “Company” or “Anaergia”) is domiciled in Canada. The Company’s registered office is at 4210 South Service Rd., Burlington, ON, L7L 4X5, Canada. The condensed consolidated interim financial statements comprise the Company and its subsidiaries (together referred to as the “Group”). The Group has entities located throughout Europe, North America, Asia, and South Africa. The Group is primarily involved in the construction of capital projects that generate renewable energy from bio-gas through advanced anaerobic digestion of organic residues from municipal, agricultural, and industrial sources.

The Company was incorporated on September 3, 2010, under the Canada Business Corporations Act. On December 21, 2018, the Company was continued under the Business Corporations Act (British Columbia), and is headquartered in Burlington, Ontario, Canada. On June 18, 2021, the Company completed its initial public offering (“IPO”), that consisted of the issuance of 12,500,000 subordinate voting shares of the Company to be listed on the Toronto Stock Exchange (the “TSX”) under the symbol ANRG.

On December 18, 2023, the Company announced a \$40,800 equity investment by Marny Investissement SA (“Marny”) by way of an arm’s-length, multiple tranche, non-brokered private placement (the “Strategic Investment”). Marny, through a wholly owned subsidiary (“Marny Holdco”), agreed to subscribe for an aggregate of 102,000,000 units of the Company (“Units”) at a price of \$0.40 per Unit with each Unit consisting of one Common Share and 1/5 of one Common Share purchase warrant of the Company (each a “Warrant”). Each Warrant entitled Marny to purchase one additional Common Share at an exercise price of \$0.80 for a period of three years following the closing of the first tranche. With the closing of the third tranche of the Strategic Investment in July 2024, Marny Holdco owned and controlled approximately 60.9% of the voting rights attached to the Subordinate Voting Shares and Multiple Voting Shares (on a non-diluted basis) and approximately 65.2% of the voting rights attached to the Subordinate Voting Shares and Multiple Voting Shares (on a partially diluted basis), assuming the exercise in full of the Warrants.

The condensed consolidated interim financial statements of the Company were authorized for issue on May 13, 2025, by the Board of Directors of the Company.

#### 2. Basis of Preparation

##### Foreign currency translation

The condensed consolidated interim financial statements are presented in Canadian Dollars, which is the Company’s reporting currency. The functional currency of the Group’s entities is the currency of their primary economic environment. Within Group entities, transactions in foreign currencies are recorded at the exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rate at the reporting date. Non-monetary assets and liabilities that are measured at fair value in a foreign currency are translated into the functional currency at the exchange rate when the fair value was determined. Non-monetary items that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the transaction. Any resulting exchange differences are recognized within the condensed consolidated interim statements of operations.

On consolidation, the assets and liabilities of foreign operations, including goodwill and fair value adjustments arising on acquisition, are translated into Canadian Dollars, being the presentation currency, at the exchange rates at the reporting date.

The income and expenses of foreign operations are translated to Canadian Dollars using average exchange rates for the month during which the transactions occurred. Foreign currency differences are recognized in other comprehensive income or loss in the cumulative translation reserve within accumulated other comprehensive income (loss).

##### Statement of compliance

The condensed consolidated interim financial statements have been prepared in accordance with and comply with IFRS<sup>(R)</sup> Accounting Standards as issued by the International Accounting Standards Board (“IASB”) (“IFRS Accounting Standards”), specifically International Accounting Standard 34, Interim Financial Reporting. These condensed consolidated interim financial statements have been prepared on the same basis, including accounting policies and methods of computation as the Group’s consolidated financial statements as at and for the year-ended December 31, 2024. Under IFRS Accounting Standards, additional disclosures are required in the annual financial statements and therefore, these condensed consolidated interim financial statements should be read in conjunction with the Group’s audited financial statements as at and for the year-ended December 31, 2024.

### Adoption of new accounting standards

The IASB and the International Financial Reporting Interpretations Committee have issued the following standards and amendments. The Group is evaluating the potential implications of the following pronouncements:

*New standards and interpretations not yet adopted*

*Amendments to IFRS 18 - Presentation and Disclosure in Financial Statements*

In April 2024, the IASB issued Presentation and Disclosure in Financial Statements (Amendments to IFRS 18), a comprehensive new accounting standard which replaces existing IAS 1, "Presentation of Financial Statements", carrying forward many of the requirements in IAS 1 unchanged and complementing them with new requirements. The changes, which mostly affect the income statement, include the requirement to classify income and expenses into three new categories, operating, investing and financing, and present subtotals for operating profit or loss and profit or loss before financing and income taxes. Further, operating expenses are presented directly on the face of the income statement and classified either by nature (e.g. employee compensation), by function (e.g. cost of sales) or using a mixed presentation. Expenses presented by function require more detailed disclosures about their nature. IFRS 18 also provides enhanced guidance for aggregation and disaggregation of information in the financial statements, introduces new disclosure requirements for management-defined performance measures and eliminates classification options for interest and dividends in the statement of cash flows. This standard is effective for annual reporting periods beginning on or after January 1, 2027. Earlier application is permitted, but will need to be disclosed. The Company is currently assessing the impact of adopting IFRS 18 on the condensed consolidated interim financial statements.

*Amendments to IFRS 9 and IFRS 7 - Classification and Measurement of Financial Instruments*

In May 2024, the IASB issued Financial Instruments (Amendments to IFRS 9) and Financial Instruments: Disclosures (Amendments to IFRS 7), relating to the classification and measurement of financial instruments, which clarify financial assets and financial liabilities are recognized and derecognized at settlement date except for regular way purchases or sales of financial assets and financial liabilities meeting conditions for new exception. The new exception permits companies to elect to derecognize certain financial liabilities settled via electronic payment systems earlier than the settlement date. They also provide guidelines to assess contractual cash flow characteristics of financial assets, which apply to all contingent cash flows, including those arising from environmental, social, and governance ESG-linked features. Additionally, these amendments introduce new disclosure requirements and update others. The amendments are effective for annual periods starting on or after January 1, 2026. Early adoption is permitted, with an option to early adopt the amendments for contingent features only. The Company is currently assessing the impact of adopting IFRS 9 and IFRS 7 on the condensed consolidated interim financial statements.

### 3. Related Parties

The Group had the following related party transactions and balances as of March 31, 2025 and December 31, 2024.

	Accounts receivable	
	Outstanding Balances at	
Related party:	March 31, 2025	December 31, 2024
Fibracast Ltd. ("Fibracast")	7	7
MD Waste Management Co Ltd *	10,557	10,557
Bioenergy Pte. Ltd	32	31
Rialto Bioenergy Facility, LLC ("Rialto")	464	—
W.M. Lyles Co.	76	494
Total	11,136	11,089

  

	Loans receivable	
	Outstanding Balances at	
Related party:	March 31, 2025	December 31, 2024
Fibracast	611	590
Loan to MD Waste Management Co Ltd., Limassol, dbT (JV partner) **	—	807
Total	611	1,397

  

	Accounts Payable	
	Outstanding Balances at	
Related party:	March 31, 2025	December 31, 2024
W.M. Lyles Co.	1,196	2,669
Fibracast	68	64
Bioenergy Pte. Ltd	100	99
Total	1,364	2,832

\* These accounts receivable with related parties are fully reserved for within the Company's expected credit losses provisions at December 31, 2024 and March 31, 2025.

\*\* These loans receivable balances with related parties are fully reserved for within the Company's expected credit losses provisions at December 31, 2024 and March 31, 2025.

The Group had the following related party transactions for the three months ended March 31, 2025 and 2024.

	Transactions for the Three Months Ended March 31,	
	2025	2024
Related party:	Revenue for goods and services	
Rialto	11	326
W.M. Lyles Co.	418	69
Total	429	395
Related party:	Purchases of goods or services	
Bioenergy Pte. Ltd	—	174
TGW Holdings ***	117	—
W.M. Lyles	1,474	108
Total	1,591	282

\*\*\* During the year ended December 31, 2024, the Company paid \$1,824 to TGW Holdings, which was recorded as a prepaid asset. Of this amount, \$117 has been recorded as an expense in the current period.

#### ***Related party guarantees***

The Company guarantees a loan that Fibracast, has received from the Ontario Government Ministry of Economic Development, Employment, and Infrastructure. The balance outstanding at March 31, 2025, was \$840 (December 31, 2024 - \$840).

The Company guarantees a loan that Fibracast received from the Economic Development of Southern Ontario in January of 2020. The loan requires monthly payments escalating from \$10 to \$100 with a balloon payment of \$118 due at maturity on June 15, 2028. The balance outstanding at March 31, 2025, was \$611 (December 31, 2024 - \$590). On July 23, 2024 the Company entered into a Back-stop Agreement with Fibracast, and PTVS Holding Corp., an investor in Fibracast. The Back-stop Agreement provides an unconditional indemnity for Anaergia's guarantee of Fibracast's loan balances with the Province of Ontario and the Federal Economic Development Agency of Southern Ontario.

The Company has guaranteed the payment obligations of Rialto for two vendors in the amount of \$3,727 as of March 31, 2025 (December 31, 2024 - \$3,727) which are recorded as liabilities on the accompanying interim condensed consolidated statements of financial position.

#### **4. Disposal and deconsolidation of subsidiaries**

##### ***Sale of Tønder***

On February 22, 2023, the Group sold its equity interests in a subsidiary of Anaergia that owned the Envo Biogas anaerobic digestion facility in Tønder, Denmark. The disposition supports the strategic decision to increase investments in new and existing projects in other European countries. The deferred consideration receivable by the Company was due on August 22, 2024 and is accrued on the accompanying condensed consolidated interim financial statements of financial position in other current assets, however this did not occur and the Company is in dispute. The Company is currently disputing certain facts and circumstances with the buyer, as a result the timing of this payment is uncertain.

## 5. Financial instruments – Fair values and risk management

### Fair values

The following table shows the carrying amounts and fair values of financial instruments, including their levels in the fair value hierarchy. It does not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value, such as short-term trade receivables and payables.

At March 31, 2025	Carrying amount	Fair Value Level 2
<b>Financial assets</b>		
Derivative asset	22	22
	<u>22</u>	<u>22</u>
<b>Financial liabilities</b>		
Derivative liability	1,141	1,141
Long-term debt	59,971	59,689
	<u>61,112</u>	<u>60,830</u>
<b>At December 31, 2024</b>	<b>Carrying amount</b>	<b>Fair Value Level 2</b>
<b>Financial assets</b>		
Derivative asset - other current assets	22	22
	<u>22</u>	<u>22</u>
<b>Financial liabilities</b>		
Derivative liability - other long-term liability	733	733
Long-term debt	60,140	61,044
	<u>60,873</u>	<u>61,777</u>

### Cash flow hedges that qualify for hedge accounting

In October 2023, the Company entered into an interest rate swap with a notional amount of US\$20,000 to swap variable rate Prime-based interest payments under its term loan for fixed interest payments bearing an interest rate of 9.04%, inclusive of the loan's applicable credit margin. The interest rate swap has a seven-year term, maturing on September 27, 2030.

The Company has designated the interest rate swap as a cash flow hedge. The effective portion of changes in the fair value of the interest rate swap (unrealized gains/losses) is recorded as a component of "Accumulated other comprehensive income (loss)." For the three months ended March 31, 2025, the Company recorded an unrealized loss on the interest rate swaps of \$393. The Company expects \$234 in losses currently recorded in accumulated other comprehensive income to be recognized in earnings over the next 12 months. The earnings impact of the interest rate derivatives designated as cash flow hedges is recorded upon the recognition of the interest related to the hedged debt. No amount of ineffectiveness was included in net loss for the three months ended March 31, 2025.

### Measurement of fair values

The fair value of the SoCal Biomethane, LLC's term loan (Live Oak Secured Indenture) was determined using a discounted cash flow model based on prevailing interest rates at the period-end date for a similar instrument.

The Company used the yield to maturity discounted cash flow analysis to estimate the fair value of the other long-term debt at March 31, 2025 and December 31, 2024. This method involves using national bank treasury yield rates and an option adjusted spread to determine the discounted cash flow for the loans to date of maturity.

The following table shows the valuation techniques used in measuring Level 2 fair values for financial instruments in the condensed consolidated interim statements of financial position, as well as the significant unobservable inputs used.

### Financial instruments measured at fair value

Type	Valuation technique	Significant unobservable inputs	Inter-relationship between significant unobservable inputs and fair value measurement
Derivative hedging instrument .....	Future cash flows	Not applicable	Not applicable

### Credit risk

Credit risk is the risk of financial loss to the Group, if a customer, borrower, or counter-party to a financial instrument fails to meet its contractual obligations and arises principally from the Group's receivables from customers. Customer credit risk is managed by each business unit subject to the Group's established policies, procedures, and controls relating to customer credit risk management.

The Group's exposure to credit risk is influenced mainly by the individual characteristics of each customer. However, management also considers the factors that may influence the credit risk of its customer base, including the default risk associated with the industry and country in which customers operate. The Group mitigates this risk through its credit policies and practices including the use of credit limits and approvals, and by monitoring the financial condition of its customers. The carrying amounts of financial assets, including accounts receivable, and contract assets represent the maximum credit exposure. The Company records a provision for estimated credit losses on loans receivable, accounts receivable and contract assets. Each provision for such losses is specific to the region's past collection history.

In addition, the Group is exposed to credit risk in relation to financial guarantee contracts given to banks on behalf of related parties. The Group's maximum exposure in this respect is the maximum amount the group could have to pay if the guarantee is called. As at March 31, 2025, an amount of \$9,145 (December 31, 2024 - \$9,145) is the total estimated loss that the Group is exposed to, however, no loss allowance was recognized in profit or loss.

#### *Liquidity risk*

Liquidity risk is the risk that the Group will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled in cash or another financial asset. The Group's exposure to this risk is mainly in respect of its trade payables, other accounts payable and accrued liabilities, long-term debt, and lease liabilities.

The Group's objective when managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Group's reputation. The Group monitors its cash flow requirements to optimize its cash return on investments. The Group aims to maintain the level of its cash and cash equivalents at an amount in excess of expected cash outflows on financial liabilities (other than trade payables) over the next 60 days. The Group also monitors the level of expected cash inflows on trade and other receivables together with expected cash outflows on trade and other payables.

#### *Market risk*

Market risk is the risk that changes in market prices (foreign exchange rates, interest rates, and equity prices) will affect the Group's income or loss or the value of its holdings of financial instruments. Market prices are subject to interest rate risk and currency risk. The Group's financial instruments which are affected by market risk include loans and borrowings, deposits, and a bond-related embedded derivative asset. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing the return.

#### *Interest rate risk*

The Company is exposed to interest rate risk on the Company's variable rate borrowings. Accordingly, interest rate fluctuations affect the amount of interest expense the Company is obligated to pay. The Company currently uses interest rate swap agreements to manage its exposure to interest rate changes. The Company has designated the interest rate swaps as cash flow hedges for accounting purposes. Accordingly, the earnings impact of the derivatives designated as cash flow hedges are recorded upon the recognition of the interest related to the hedged debt. There was no significant ineffectiveness in the three months ended March 31, 2025.

Taking the Company's interest rate swap into account, a sensitivity analysis of the impact on the Company's variable rate corporate debt instruments to a hypothetical 100 basis point increase in short-term rates (Prime) for the three months ended March 31, 2025 would have resulted in no significant increase in interest expense.

#### *Currency risk*

Foreign exchange risk arises from future commercial transactions and recognized assets and liabilities denominated in a currency that is not the functional currency of the relevant Group entity. The Group operates internationally and is exposed to the risk that the fair value or future cash flows of an exposure will fluctuate due to changes in foreign exchange rates. The Group monitors its exposure to currency risk and reviews whether the use of derivative financial instruments is appropriate to manage potential fluctuations in foreign exchange rates.

#### *Analysis of other accumulated comprehensive income*

The below table sets out the reconciliation of each component of other accumulated comprehensive income (loss) and the analysis of other comprehensive income (loss) (all of which are attributable to the equity owners of the Group):

	Foreign currency translation reserve	Cash flow hedging reserve
<b>As of January 1, 2024</b>	<b>18,259</b>	<b>(317)</b>
Foreign currency revaluation of the foreign operations	(597)	—
Foreign currency effect of profit sharing adjustments	(54)	—
Fair value losses related to hedging transaction	—	1,180
<b>As of December 31, 2024</b>	<b>17,608</b>	<b>863</b>
Foreign currency revaluation of the foreign operations	(3,056)	—
Foreign currency effect of profit sharing adjustments	(65)	—
Fair value gains related to hedging transaction	—	(1,175)
<b>As of March 31, 2025</b>	<b>14,487</b>	<b>(312)</b>

## 6. Non-financial assets

### Property, plant and equipment

The following table presents the summary of property, plant and equipment and related accumulated depreciation for the three months ended March 31, 2025:

	Property \$	Building and leasehold improvements \$	Office furniture and equipment \$	Equipment and machinery \$	Construction work-in- progress \$	Other assets and vehicles \$	Total \$
<b>Cost</b>							
Balance at January 1, 2025	15,769	9,986	5,564	100,949	38,625	1,749	172,642
Additions	11	—	14	9	71	218	323
Disposals	—	—	—	—	—	16	16
Other adjustments	—	—	(6)	(165)	(500)	—	(671)
Exchange adjustment	968	79	381	(232)	(230)	404	1,370
<b>Balance at March 31, 2025</b>	<b>16,748</b>	<b>10,065</b>	<b>5,953</b>	<b>100,561</b>	<b>37,966</b>	<b>2,387</b>	<b>173,680</b>
<b>Accumulated depreciation, amortization and impairment</b>							
Balance at January 1, 2025	6,273	3,466	5,504	17,480	30,317	1,399	64,439
Depreciation and amortization	428	117	70	770	—	37	1,422
Disposals	—	—	—	—	—	16	16
Other adjustments	—	—	(6)	—	—	—	(6)
Exchange adjustment	90	7	46	106	14	42	305
<b>Balance at March 31, 2025</b>	<b>6,791</b>	<b>3,590</b>	<b>5,614</b>	<b>18,356</b>	<b>30,331</b>	<b>1,494</b>	<b>66,176</b>
<b>Carrying amounts</b>							
<b>At January 1, 2025</b>	<b>9,496</b>	<b>6,520</b>	<b>60</b>	<b>83,469</b>	<b>8,308</b>	<b>350</b>	<b>108,203</b>
<b>At March 31, 2025</b>	<b>9,957</b>	<b>6,475</b>	<b>339</b>	<b>82,205</b>	<b>7,635</b>	<b>893</b>	<b>107,504</b>
<b>Of which: Net book value of right of use assets included in property, plant and equipment at March 31, 2025</b>	<b>9,957</b>	<b>—</b>	<b>—</b>	<b>—</b>	<b>—</b>	<b>132</b>	<b>10,089</b>

### Intangible Assets

The following table presents the summary of intangible assets and related accumulated amortization for the three months ended March 31, 2025:

	Patents \$	Computer Software and Licenses \$	Other Intangible Assets \$	Total \$
<b>Cost</b>				
As of January 1, 2025	4,250	2,164	2,806	9,220
Additions	11	2	—	13
Exchange adjustment	21	54	2	77
<b>As of March 31, 2025</b>	<b>4,282</b>	<b>2,220</b>	<b>2,808</b>	<b>9,310</b>
<b>Accumulated amortization and impairment</b>				
As of January 1, 2025	2,160	2,107	2,393	6,660
Amortization	40	16	2	58
Exchange adjustment	21	52	3	76
<b>As of March 31, 2025</b>	<b>2,221</b>	<b>2,175</b>	<b>2,398</b>	<b>6,794</b>
<b>Carrying amount</b>				
At January 1, 2025	2,090	57	413	2,560
<b>At March 31, 2025</b>	<b>2,061</b>	<b>45</b>	<b>410</b>	<b>2,516</b>

### Impairment

There has been no impairment charge for the three months ended March 31, 2025 and 2024, and there were no indicators of impairment identified as a result of the Company's review of events and circumstances related to its existing assets.

## 7. Equity-accounted investees

On October 25, 2023, Fibracast completed a private placement offering with a third-party which valued the Company's equity method investee at \$63,000 and diluted the Company's ownership to 20.5%. During the year ended December 31, 2024, the Company recognized losses from Fibracast of \$1,062 and recognized impairment of \$6,244. Due to the dilution of the Company's investment in Fibracast during 2024 that reduced the ownership to be 4.0%, the investment has been updated to the cost method of accounting as of December 31, 2024 and the remaining balance of \$2,584 has been reclassified to other long-term assets.

## 8. Long-term debt

### *Terms and repayment schedule*

The terms and conditions of outstanding loans and borrowings are as follows:

	Nominal interest rate	Year of maturity	Note	March 31, 2025 Carrying amount	December 31, 2024 Carrying amount
Rhode Island Project Financing Term Loan	Prime plus 1.25%	2030	(a)	28,782	28,770
Live Oak Indenture	5.96%	2032	(b)	13,657	14,031
SoCal Organics Recycling Facility	4.00%	2033	(c)	12,920	13,259
Caterpillar Financial Services Term Loans	5.70% - 6.69%	2025 - 2028	(d)	4,455	4,707
Other	0% - 11.4%	2023 - 2027		808	116
				60,622	60,883
Less: issuance costs				(651)	(743)
Total long-term debt				59,971	60,140
Of which:					
Current				32,258	32,334
Long term				27,713	27,806

### (a) Rhode Island Project Financing Term Loan

On September 28, 2023, the Company through its subsidiary, Rhode Island Bioenergy Facility ("RIBF"), closed a US\$20,000 term loan (the "Term Loan") with East West Bank, a California Corporation, to finance remaining construction and commissioning of the RIBF project in the Town of Johnston, Rhode Island, USA and working capital. This financing has a seven-year term, and bears interest on US Dollar denominated drawn funds at an annual rate equal to the prime rate as published in the Wall Street Journal (or another similar publication selected by the lender) plus 1.25%, subject to adjustment based on a swap agreement to be entered into within ten days after closing, and a floor of 7.5%. The loan is subject to certain positive and negative covenants that are customary for transactions of this nature, including liens and security interests in assets of RIBF. The financial covenants for this Term Loan are not effective until June 30, 2025, resulting from an amendment and restatement of the initial term loan agreements executed on September 30, 2024. On October 13, 2023, the Company executed an interest rate swap agreement with East West Bank which effectively fixes the interest on the Loan at 9.04%. Due to the Company not being in compliance with certain production covenants during the fourth quarter of fiscal year 2024 and the first quarter of fiscal year 2025, this loan is classified as current as of March 31, 2025. Subsequent to the balance sheet date the Company requested and was granted a waiver of this covenant as of March 31, 2025. While the provided waiver grants relief from the covenant for the first quarter of fiscal year 2025, the Company recognizes that it was within the rights of East West Bank to call the loan as of March 31, 2025. The Company expects that it will continue to not be in compliance with this production covenant as of June 30, 2025.

### (b) Live Oak Secured Indenture

The Company's subsidiary, SoCal Biomethane, LLC entered into a credit agreement with Live Oak Banking Corporation. The credit agreement allows SoCal Biomethane, LLC to borrow up to US\$13,000 at a fixed interest rate of 5.96% per annum maturing June 1, 2032. The credit agreement calls for the Company to pay a declining prepayment premium that starts at 4% and declines 1% each year over the first four years of the agreement. The prepayment premium was recognized as an embedded derivative and is accounted for at FVTPL. During the year ended December 31, 2022, SoCal Biomethane, LLC has borrowed US\$12,706 and has fully utilized the loan. The indenture is secured by the assets of SoCal Biomethane, LLC. The loan has certain financial covenants including a maximum debt to worth ratio of less than 5:1, a minimum current ratio of greater than one, and minimum debt service coverage ratio of greater than 1.25. As of March 31, 2025, the Company's subsidiary was in compliance with these covenants.

### (c) SoCal Organics Recycling Facility Loan

On February 2, 2023, the Company's subsidiary SoCal Organics Recycling Facility, LLC ("SCORF") entered into a US\$10,000 loan and security with the State of California, Department of Resources Recycling and Recovery. The loan matures on February 1, 2033 and bears interest of 4.0% per annum. The loan is secured by a piece of equipment that is being leased to a third-party for US\$3,000 over 10 years. The equipment is currently in the process of being installed in Santa Fe Springs, California. The loan is guaranteed by the Company's subsidiary, UTS Bioenergy Holdings, LLC, and SoCal Organics Recycling Facility, LLC's ultimate US parent. The guarantee will expire when the loan matures. This loan has certain affirmative covenants, which the Company was in compliance with at March 31, 2025. The loan requires interest only payments until March 1, 2024 and then the loan amortizes over the remaining term with a monthly payment of US\$110.

**(d) Caterpillar Financial Services Corporation**

The Company's subsidiary, Biogas Power Mojave Systems, LLC entered a 10-year Term Loan Financing Agreement for a maximum loan amount of USD \$4,504 at a fixed annual rate of 6.69%, repayable monthly. The Company's subsidiary, Escondido Bioenergy Facility, LLC, entered a 10-year Term Loan Financing Agreement for USD \$4,000 at a fixed annual rate of 5.70%, repayable monthly. Both of these loans have certain financial covenants including a debt service coverage ratio of 1.3 and a minimum tangible member's equity (for Escondido) of greater than \$0 or a total liabilities to tangible members equity ratio (for Biogas Power Mojave Systems) of no greater than 2.0. As of March 31, 2025, the Company's was not in compliance with the financial covenant related to tangible members equity ratio, but had obtained a waiver of this covenant before the end of the first quarter which is effective through September 30, 2025.

The loans are secured by promissory notes and a first priority security interest as collateral in all rights, title, and interest of Biogas Power Mojave Systems, LLC and Escondido Bioenergy Facility, LLC in the projects including equipment, related software and other tangible and intangible properties.

*Repayment of Principal and Interest*

The repayment of principal and interest on the outstanding loans and borrowings is as follows:

<b>Repayment Period</b>	<b>Principal</b>	<b>Interest</b>	<b>Total Repayment</b>
12 months after period end	32,274	3,269	35,543
13-24 months after period end	3,929	633	4,562
25-36 months after period end	3,708	547	4,255
37-48 months after period end	6,248	413	6,661
49-60 months after period end	3,660	246	3,906
Thereafter	10,803	320	11,123
	<u>60,622</u>	<u>5,428</u>	<u>66,050</u>

*Reconciliation of movements of liabilities to cash flows arising from financing activities*

The following is a reconciliation between the opening and closing balances for liabilities arising from financing activities, net of debt transaction costs:

	<b>Rhode Island Project Financing Term Loan</b>	<b>Live Oak Indenture</b>	<b>SoCal Organics Recycling Facility</b>	<b>Other long-term debt</b>	<b>Total</b>
Balance at January 1, 2025	27,929	14,711	12,744	4,756	60,140
Remeasurement	—	—	—	792	792
Repayment of debt	—	(380)	(346)	(361)	(1,087)
Interest paid	(676)	(224)	(132)	(72)	(1,104)
Foreign exchange adjustments	11	5	7	43	66
Interest accrual	710	243	133	78	1,164
Balance at March 31, 2025	<u>27,974</u>	<u>14,355</u>	<u>12,406</u>	<u>5,236</u>	<u>59,971</u>

**9. Equity**

*Share capital and contributed surplus*

	<b>Common shares (previously Subordinate voting shares)</b>		<b>Contributed Surplus</b>
	<b># (000's)</b>	<b>\$ (000's)</b>	<b>\$ (000's)</b>
<b>Balance as at January 1, 2025</b>	<u>169,789</u>	<u>439,315</u>	<u>7,350</u>
Stock compensation expense	—	—	250
RSU Vesting and Option Exercises	50	45	(44)
<b>Balance as at March 31, 2025</b>	<u>169,839</u>	<u>439,360</u>	<u>7,556</u>

*Subordinate and Multiple Voting Shares*

The Subordinate Voting Shares and the Multiple Voting Shares were identical with the exception of the multiple voting, pre-emptive and conversion rights attached to the Multiple Voting Shares. Each Subordinate Voting Share was entitled to one vote and each Multiple Voting Share was entitled to four votes on all matters upon which each such class of shares were entitled to vote. The Multiple Voting Shares were convertible into Subordinate Voting Shares on a one-for-one basis at any time at the option of the holders thereof and automatically in certain other circumstances. The Multiple Voting Shares ranked pari passu with respect to the payment of dividends, return of capital and distribution of assets in the event of a liquidation,



dissolution or winding up of the Company. The holders of Subordinate Voting Shares benefited from certain provisions that gave them certain rights in the event of a take-over bid for the Multiple Voting Shares.

### ***Strategic Investment***

On December 18, 2023, the Company announced a \$40,800 equity investment by Marny by way of an arm's-length, multi-tranche, non-brokered private placement (the "Strategic Investment").

Marny, through Marny Holdco, had agreed to subscribe for an aggregate of 102,000,000 units of the Company ("Units") at a price of \$0.40 per Unit with each Unit consisting of one Subordinate Voting Share of the Company and 1/5 of one Subordinate Voting Share purchase warrant of the Company (each a "Warrant"). Each Warrant will entitle Marny to purchase one additional Subordinate Voting Share at an exercise price of \$0.80 for a period of three years following the closing of the first tranche. The Unit subscription price of \$0.40 represents a 57% premium to the 10-day volume weighted average price of the Subordinate Voting Shares on the Toronto Stock Exchange ("TSX") as of transaction date.

Marny has the right, in its sole discretion, to allocate an aggregate of 10,200,000 of the Subordinate Voting Shares for which it has subscribed to certain individual investors (the "Marny Individual Investors"), and any such Marny Individual Investors shall grant an irrevocable proxy to Marny Holdco in respect of the voting rights for such Subordinate Voting Shares.

On February 2, 2024, the first tranche of the Strategic Investment from Marny closed with the issuance of 31,250,000 Units for gross proceeds of \$12,502. Each Unit consists of one Subordinate Voting Share and one Warrant.

### ***Non-controlling Interest***

Non-controlling interests consisted of the following amounts by entity at:

<b>Non-controlling interest</b>	<b>March 31, 2025</b>	<b>December 31, 2024</b>
Anaergia Bioenergy Facilities, LLC	89,235	89,056
Rhode Island Holdco, LLC	23,309	23,265
Other entities	(1,471)	(1,471)
	<u>111,073</u>	<u>110,850</u>

### ***Anaergia Bioenergy Facility, LLC***

On August 3, 2022, Anaergia Services, LLC ("AS") entered into a Contribution and Investment Agreement ("CIA") with IIF Anaergia Holdco, LLC, and with Anaergia Bioenergy Facilities, LLC ("ABF"), a subsidiary of the Company. The CIA provides for the transfer and contribution of the interests of AS in SoCal Biomethane Holdco, LLC ("SCH") and Charlotte Bioenergy Facility Holdco, LLC into ABF. On November 18, 2022, AS contributed its ownership interests in Rhode Island Bioenergy Holdco, LLC ("RIBFH") into ABF. The non-controlling interest exchanged its existing preferred interest in SCH for its preferred interest in ABF, in addition to making additional investments in ABF preferred units in the year. On December 7, 2023, the non-controlling preferred interest holders and the Company entered into a second amended and restated limited liability agreement between the parties. As part of this amended LLC agreement, the parties agreed to a preferred equity membership percentage and agreed to split out RIBFH into a separate investment vehicle with similar terms and conditions as ABF (See below RIBFH section). Non-controlling interest on the condensed consolidated interim statements of financial position is calculated based upon the waterfall mechanism agreed by the parties.

Another subsidiary of the Company, Anaergia Future Fuel, LLC ("AFF"), is a party to a profit sharing arrangement in ABF, the distributable cash flow will be distributed for ABF in the following way:

- First, 100% distributed to the preferred members in proportion to each members aggregate invested capital until the balance of each preferred members invested capital has been reduced to zero;
- Second, 80% to the preferred members in proportion to their invested capital and 20% to the common equity holder (AFF) until each preferred member receives an internal rate of return of 10%;
- Third, 50% to the preferred members in proportion to their invested capital and 50% to the common equity holder (AFF) until each preferred member receives an internal rate of return of 14%;
- Thereafter, 20% to the preferred members in proportion to their invested capital and 80% to the common equity holder (AFF).

Currently, the above mentioned proportionate share of preferred equity is split at a ratio of approximately 65% for non-controlling interest and 35% for AFF, which owns 100% of the common equity of ABF. The effects of this profit sharing arrangement are reflected as adjustments between non-controlling interest and deficit in the condensed consolidated interim statements of changes in equity. During the three months ended March 31, 2025, the Company recognized a decrease in its deficit in the amount of \$894 with a corresponding decrease in the non-controlling interest in connection with the profit sharing arrangement. No further changes have been made as of March 31, 2025.

### ***Rhode Island Bioenergy Facility Holdco, LLC ("RIBFH")***

On December 7, 2023, the non-controlling preferred interest holders in ABF and the Company entered into an amended and restated limited liability agreement of RIBFH. As part of this LLC agreement, the parties agreed to split out RIBFH as separate entity from ABF above and agreed to a preferred equity membership percentage (65% for the non-controlling interest to 35% for AFF, which owns 100% of the common equity of RIBFH). Non-controlling interest on the condensed consolidated interim statements of financial position is calculated based upon the waterfall mechanism agreed by the Group and non-controlling interest in the LLC agreement.

The Group is a party to a profit sharing arrangement in RIBFH, the distributable cash flow will be distributed for RIBFH in the following way:

- First, 100% distributed to the preferred members in proportion to each members aggregate invested capital until the balance of each preferred members invested capital has been reduced to zero;
- Second, 80% to the preferred members in proportion to their invested capital and 20% to the common equity holder (AFF) until each preferred member receives an internal rate of return of 10%;
- Third, 50% to the preferred members in proportion to their invested capital and 50% to the common equity holder (AFF) until each preferred member receives an internal rate of return of 14%;
- Thereafter, 20% to the preferred members in proportion to their invested capital and 80% to the common equity holder (AFF).

The effects of this profit sharing arrangement are reflected as adjustments between non-controlling interest and deficit in the condensed consolidated interim statements of changes in equity. During the three months ended March 31, 2025, the Company recognized a decrease in its deficit in the amount of \$1,965 with a corresponding decrease in the non-controlling interest in connection with the profit sharing arrangement. During the three months ended March 31, 2025, the Company's preferred equity partners contributed \$1,419. No further changes have been made as of March 31, 2025.

### **10. Share-based payment plans**

#### ***Employee Stock Options Plan ("ESOP")***

The Company has an Employees Stock Options Plan ("ESOP") under which certain of its employees (including those of its subsidiary entities) were granted a total of 669,763 Common stock options at a nominal exercise price. Under the terms of ESOP, the shares vest 25% per annum over four years. During the three months ended March 31, 2025, option holders of the Company's ESOP exercised options for 50,000 (2024 - 25,000) subordinate voting shares, for proceeds of \$1 (2024 - \$0). As result of the exercises, the Company reclassified \$44 from contributed surplus to issued capital.

#### ***2021 Omnibus Equity Incentive Plan***

On June 16, 2021, the Group adopted the Omnibus Equity Incentive Plan (the "2021 Plan") that allows the Company to grant equity awards including restricted stock units, performance share units, dividend share units and stock options to employees, directors, and consultants of the Company, that if converted would be exercised into subordinate voting shares, now common shares, of the Company. The amount available under the 2021 Plan is limited to 10% of the issued and outstanding shares of the combined subordinate voting shares and multiple voting shares less any amount for outstanding Legacy Options for the ESOP or outstanding under the 2021 plan. The equity awards under the 2021 Plan are subject to three year service based vesting.

#### ***Share Issuance Plans(equity-settled)***

At March 31, 2025, the Company had two share-based payment arrangements, which are described below.

Type of arrangement	Awards granted	Type of Awards	Contractual life	Vesting conditions
Employee Stock Option Plan ("ESOP")	669,763	Stock options	Earlier of 15 years or December 31, 2025	Four years' service
2021 Omnibus Equity Incentive Plan ("2021 Plan")	5,836,881	Restricted stock units	Indefinite	Three years' service

Further details and activity of the share option and restricted stock unit plans for the three months ended March 31, 2025 and 2024:

	Number of Options	ESOP Weighted Average Exercise Price	Weighted Average Fair Value	2021 Plan Number of Awards	Weighted Average Fair Value	Total Number of Awards
Outstanding at January 1, 2025	767,163	\$ 0.01	\$ 2.72	5,974,882	\$ 0.80	6,742,045
Vested and Released	—	—	—	(931)	—	(931)
Exercised	(50,000)	0.01	2.72	—	—	(50,000)
Cancelled/forfeited	(47,400)	0.01	2.72	(137,070)	0.64	(184,470)
Outstanding at March 31, 2025	669,763	\$ 0.01	\$ 2.72	5,836,881	\$ 0.99	6,506,644
Exercisable/Vested at March 31, 2025	669,763	\$ 0.01	\$ 2.72	—	\$ —	669,763

	Number of Options	ESOP Weighted Average Exercise Price	Weighted Average Fair Value	2021 Plan Number of Awards	Weighted Average Fair Value	Total Number of Awards
Outstanding at January 1, 2024	1,600,674	\$ 0.01	\$ 2.72	3,841,298	\$ 1.84	5,441,972
Granted	—	—	—	257,022	0.27	257,022
Exercised	(25,000)	0.01	2.72	—	—	(25,000)
Outstanding at March 31, 2024	1,575,674	\$ 0.01	\$ 2.72	4,098,320	\$ 1.74	5,673,994
Exercisable/Vested at March 31, 2024	1,575,674	\$ 0.01	\$ 2.72	\$ —	\$ —	1,575,674

For the three months ended March 31, 2025 and 2024 the weighted average share price at the date of exercise for share options exercised during the period was \$0.90 and \$0.25, respectively. The options outstanding at March 31, 2025 had an exercise price of \$0.01, and a weighted average remaining contractual life of 0.75 years. At March 31, 2025, the weighted average remaining recognition period for the restricted stock units issued under the 2021 plan was 2.22 years.

#### Expense recognized in profit and loss

Share-based payment expenses by plan for the three months ended March 31, 2025 and 2024 were as follows:

	Three Months Ended March 31, 2025		
	ESOP \$	2021 Plan \$	Total \$
Expense arising from RSUs	—	250	250
Total expense	—	250	250

  

	Three Months Ended March 31, 2024		
	ESOP \$	2021 Plan \$	Total \$
Expense arising from RSUs	—	589	589
Total expense	—	589	589

## 11. Commitments and Contingencies

	Three Months Ended March 31, 2025	Year Ended December 31, 2024
Financial Guarantee contracts	14,127	14,127
Contingent liabilities and legal claims	4,389	4,541
Performance bonds	50,035	53,124
Total	68,551	71,792

#### Financial Guarantee contracts

Financial guarantee contracts are agreements and/or commitments to reimburse or make payment on account of any losses or non-payments by a borrower in an event of default scenario and include surety guarantees in connection with transactions between two parties. These include a letter of patronage for customer, that guarantee sufficient capital for performance on a revenue contract. In addition, the Company has additional financial guarantee contracts in the form of indemnity agreements from insurance carriers related to the Company's performance bonds, discussed below.

#### Contingent liabilities and legal claims

The Group is engaged in litigation in various other legal matters. The legal proceedings are in different stages of progress, and the eventual outcome of such litigation, at this point in time, is uncertain. The amount detailed here represents the full amount of claims made by third-parties for various legal claims. The aggregate amount of known claims involved in these disputes are material and full provision for expected expenses has been made wherever considered necessary.

### *Performance bonds*

Performance bonds are financial guarantee contracts issued on behalf of the Group by financial institutions for Anaergia, Inc. and Anaergia S.r.L. for the Group's capital sales and build-own-operate segments. These performance bonds typically provide collateral or other security in order for the financial institution to issue the bond. Only upon the Group's non-performance can the bonds be drawn and the collateral seized.

### *Legal claims*

On March 27, 2023, a statement of claim was issued (under the Class Proceedings Act, 1992) in the Ontario Superior Court of Justice against the Company and others, involving an order for leave to proceed under the Securities Act (Ontario), certifying the proceeding as a class proceeding and appointing a representative plaintiff who claims damages and other relief pertaining to primary and secondary market financial disclosures relating to proposed class period from June 7, 2021 to November 8, 2022. The plaintiff's claim was last amended in March 2024. The plaintiff's claim includes allegations of both primary and secondary market misrepresentation under sections 130(1) and 138.3(1) of the Ontario Securities Act in respect of the Company's financial reporting and guidance. A hearing on the plaintiff's motions for leave to pursue the secondary market misrepresentation claims and certification of the class action was held in April 2025 in Brampton, Ontario. The Company's motion for summary judgment to dismiss the primary market misrepresentation claims on limitations grounds was heard at the same time. The Company intends to continue vigorously defending against the claim. As of March 31, 2025 and December 31, 2024, the Company has accrued a provision for the insurance deductible given the status of the claim and the likely outflow of \$471.

The Company's management believes that adequate provisions for legal claims have been recorded in the interim condensed consolidated financial statements where required. The Group also maintains comprehensive insurance coverage which may be available to reimburse actual expenditures in certain circumstances.

## **12. Segment reporting**

The Group determines its reportable segments based on the nature of operations and includes three operating segments: Capital Sales, Operation and Maintenance Services, and Build, Own, and Operate Projects.

Capital Sales consists of the sales of proprietary technology solutions and services to third party customers, predominantly municipalities, private entities, and project developers.

Operation and Maintenance Services consist of third-party recurring services contracts to operate and maintain the technology solutions.

Build, Own, and Operate Projects consist of greenfield or brownfield facilities that the Group builds and operates to fulfill long-term contracts to supply energy to third parties.

The financial results of the business segments are included below. Performance is measured based on gross profit as reported to the Group's Chief Executive Officer, who acts as the Chief Operating Decision Maker.

### *Segment revenues and profits*

The following is an analysis of the Group's revenue and results by reportable segment for the three months ended March 31, 2025 and 2024:

	<b>Revenue</b>		<b>Gross Profit (Loss)</b>	
	<b>Three Months Ended March 31,</b>		<b>Three Months Ended March 31,</b>	
	<b>2025</b>	<b>2024</b>	<b>2025</b>	<b>2024</b>
Capital Sales	16,074	16,367	4,305	1,979
O&M Services	4,804	4,546	1,667	1,739
Build, Own, and Operate	3,998	4,056	(569)	2,762
Total	24,876	24,969	5,403	6,480

The following is an analysis of the Group's total assets by reportable segment at March 31, 2025 and December 31, 2024:

	<b>Capital Sales</b>	<b>O&amp;M Services</b>	<b>Build, Own, and Operate</b>	<b>Other</b>	<b>Total</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>
At March 31, 2025	65,402	78,981	89,566	(10,919)	223,030
At December 31, 2024	97,370	48,348	90,847	(3,238)	233,327

## Geographical information

The Group's revenue from external customers and information about its segment assets (non-current assets excluding financial instruments, deferred tax assets, and other financial assets) by geographical location are detailed below:

Geographic Region	Revenue		Non-current Assets	
	Three Months Ended March 31,		As of	As of
	2025	2024	March 31, 2025	December 31, 2024
North America	16,706	14,495	107,899	108,701
Italy	3,495	4,561	613	608
Other EMEA	3,345	3,629	1,123	1,080
APAC	1,330	2,284	385	374
Total	24,876	24,969	110,020	110,763

## 13. Earnings per share

Basic earnings per share is calculated by dividing the profit or loss attributable to equity holders of the Group by the weighted-average number of common shares outstanding during the year. Diluted earnings per share are calculated by using the treasury stock method. The treasury stock method assumes that any proceeds obtained on exercise of equity-based compensation arrangements would be used to purchase common shares at the average market price during the period. The weighted-average number of shares outstanding is then adjusted by the difference between the number of shares issued from the exercise of equity-based compensation arrangements and shares repurchased from the related proceeds.

The below profit sharing adjustment to net loss attributable to shareholders is the adjustment for the profit sharing arrangement with the Company's preferred equity interest holders at the Group's subsidiaries, as these instruments are deemed to be participating securities. Preferred equity interests in the Company's subsidiaries are to be distributed first to the preferred equity holders, which in both the cases of ABF and RIBFH would be distributed first to non-controlling interests at a ratio of approximately 65% to 35%. See Note 9 for additional information on the profit sharing arrangements.

In thousands of Canadian Dollars except share amounts	Three Months Ended March 31,	
	2025	2024
Net loss	(5,897)	(11,481)
Effect of profit sharing arrangement and preferred equity interests adjustment	2,912	4,096
Loss available for ordinary shareholders - basic and dilutive	(2,985)	(7,385)
Weighted average Common Shares	169,839,016	85,208,288
Total ordinary shares	169,839,016	85,208,288

  

	Three Months Ended March 31,	
	2025	2024
Basic and diluted loss per share	\$ (0.02)	\$ (0.09)

Instruments excluded because they are considered anti-dilutive:

Instruments:	Three Months Ended March 31,	
	2025	2024
Restricted stock units	5,836,881	4,098,320
Share purchase warrants - Marny	20,400,000	6,250,000
Common stock options outstanding	663,427	1,515,971
	26,900,308	11,864,291

#### 14. Net change in operating assets and liabilities

The table below reconciles the change in current assets and liabilities as shown in the condensed consolidated interim statements of cash flows.

	Three Months Ended March 31,	
	2025	2024
	\$	\$
Net change in operating assets and liabilities		
Decrease (increase) in accounts receivable	(1,637)	11,439
Decrease (increase) in contract assets	(3,287)	10,696
Decrease (increase) in prepaid expenses	882	489
Increase in inventory	(1,383)	(416)
Increase in other current assets	(1,803)	(497)
Increase (decrease) in accounts payable	725	(12,680)
Decrease in accrued liabilities and provisions	(3,443)	(12,617)
Increase (decrease) in contract liabilities	4,611	(195)
Increase in accrued interest	1,164	47
Increase in property, plant and equipment included in accounts payable	—	95
Others	1,575	(81)
	<u>(2,596)</u>	<u>(3,720)</u>

#### 15. Subsequent events

In connection with the preparation of the financial statements, the Company has evaluated events that occurred subsequent to March 31, 2025 through the date on which these financial statements were issued to determine whether any of these events required adjustments to or disclosure in the financial statements. There were no reportable subsequent events or transactions.